BioCentury | Mar 25, 2019
Distillery Therapeutics

IL-17RD or inhibition of ZEB1 to sensitize lung cancer to MEK inhibition

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest IL-17RD or blocking ZEB1 via miR-200 expression or HDAC inhibition could sensitize lung cancer to MEK inhibitors. In tumor samples from...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Biomarkers

...eight healthy volunteers identified a panel of five miRNAs - microRNA-106a (miR-106a) , miR-135a , miR-200c...
...2016 doi:10.1073/pnas.1611596113 CONTACT: Joshua J. Meeks, Northwestern University , Chicago, Ill. email: joshua.meeks@northwestern.edu Esme Gaisford MicroRNA-106a (miR-106a) MicroRNA-135a (miR-135a) MicroRNA-200c (miR-200c) MicroRNA-433...
BioCentury | Aug 11, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-9 (miR-9); miR-200c

...Cancer INDICATION: Breast cancer Patient sample and mouse studies suggest inhibiting miR-9 or promoting miR-200c expression...
...of miR-200c decreased the formation of vascular-like structures compared with a scrambled oligonucleotide or normal miR-200c...
...molecule miR-9 inhibitors or miR-200c promoters in animal models of TNBC. TARGET/MARKER/PATHWAY: MicroRNA-9 (miR-9) ; miR-200c...
BioCentury | Jun 30, 2016
Distillery Techniques

Techniques: A 15-microRNA (miRNA) signature to predict survival in patients with colon, pancreatic and stomach cancers

Biomarkers TECHNOLOGY: Gene profiling A 15-microRNA signature associated with high doublecortin-like kinase 1 (DCLK1) activity could help predict survival in colon, pancreatic and stomach cancers. In colon, esophageal, pancreatic, rectal and stomach tumor samples from...
BioCentury | Sep 10, 2015
Distillery Therapeutics

Therapeutics: MicroRNA-200 (miR-200)

Endocrine/metabolic disease INDICATION: Diabetes In vitro studies suggest inhibiting miR-200 could help treat DNA damage-induced complications of Type I diabetes. Serum levels of miR-200 were higher in fibroblasts and induced pluripotent stem (iPS) cells from...
BioCentury | Jul 10, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Low ERBB receptor feedback inhibitor 1 (ERRFI1; MIG6) to microRNA-200 (miR-200) ratio predicts response of cancers with wild-type epidermal growth factor receptor (EGFR) to EGFR inhibition...
BioCentury | Dec 12, 2013
Distillery Techniques

Technology: Drug platforms

...in human embryonic and leukemia cells. In breast cancer cells, TALEN pairs targeting miR-141 and miR-200C...
BioCentury | Jul 1, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MicroRNA-200 (miR-200); Fas receptor (CD95); protein tyrosine phosphatase non-receptor type 13 (PTPN13; FAP-1) In vitro studies suggest that boosting miR-200 expression could help to...
BioCentury | Sep 24, 2009
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer MicroRNA-200 (miRNA-200) A study in mice suggests that increasing expression of miRNA-200 could help prevent cancer metastasis. miRNA profiling showed downregulated expression of miRNA-200...
BioCentury | Aug 27, 2009
Distillery Therapeutics

Indication: Cancer

...Licensing status Publication and contact nformation Cancer Breast cancer BMI1 polycomb ring finger oncogene (BMI1); microRNA-200c...
Items per page:
1 - 10 of 11